Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
15 Dec 2017
Change (% chg)

$0.02 (+1.18%)
Prev Close
$1.69
Open
$1.69
Day's High
$1.72
Day's Low
$1.69
Volume
27,547
Avg. Vol
89,330
52-wk High
$4.68
52-wk Low
$1.35

Chart for

About

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through... (more)
No analyst recommendations are available for .

Overall

Beta: -0.47
Market Cap(Mil.): $35.12
Shares Outstanding(Mil.): 20.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

Allergan may pursue lawsuit against drug compounder Imprimis

Allergan PLC can proceed with a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug, Restasis, a federal judge has ruled.

Nov 16 2017

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

Nov 14 2017

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

Oct 19 2017

UPDATE 3-Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

Oct 19 2017

BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1‍​

* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1‍​ Further company coverage:

Oct 19 2017

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis.

Oct 19 2017

BRIEF-Imprimis Pharmaceuticals to offer compounded Cyclosporine alternative to Restasis

* Imprimis Pharmaceuticals-‍making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis​ Source text for Eikon: Further company coverage:

Oct 19 2017

BRIEF-FDA Curcumin Investigation supports Imprimis statement

* Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​

Sep 14 2017

BRIEF-Imprimis Pharmaceuticals ‍responded to Allergan Plc press release regarding lawsuit

* Imprimis Pharmaceuticals Inc - ‍responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis​

Sep 11 2017

BRIEF-Allergan USA files suits against Imprimis, Prescriber's Choice and Sincerus Florida

* Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC

Sep 07 2017

Competitors

  Price Chg
Eli Lilly and Co (LLY.N) $86.54 +0.04
Sanofi SA (SASY.PA) €73.55 -0.22
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Novartis AG (NOVN.S) CHF83.80 -0.05

Earnings vs. Estimates